Vanda Pharmaceutical’s Nereus may soon break out of its motion sickness niche to become a treatment option for the burgeoning ...

Things have been relatively quiet on the layoff front for the company in 2026, although it was widely reported in June that ...

Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...

The new pact will see Regeneron provide doses of the drug—which includes atoltivimab, maftivimab and odesivimab-ebgn—through 2031. In exchange, the company is in line to receive roughly $270 million ...

A U.S. judge has ruled Eli Lilly can keep making marketing claims challenged by Novo pending a ruling on a court case brought ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

As it continues to confront a potential existential threat in the United States, CRDMO juggernaut WuXi AppTec’s finances ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September.  | In new ...

With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...